SEC Form 4 · accession 0001209191-17-059474
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Nov 2, 2017
Accepted (ET)
Nov 6, 2017 · 5:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2017 | M | 1,796 | $91.05 | A | 56,220 | D | |
| Common StockF2,F3 | Nov 2, 2017 | S | 400 | $143.54 | D | 55,820 | D | |
| Common StockF3,F4 | Nov 2, 2017 | S | 1,096 | $144.89 | D | 54,724 | D | |
| Common StockF3,F5 | Nov 2, 2017 | S | 300 | $145.89 | D | 54,424 | D | |
| Common Stock | Nov 3, 2017 | M | 3,594 | $109.14 | A | 58,018 | D | |
| Common StockF3,F6 | Nov 3, 2017 | S | 3,594 | $144.69 | D | 54,424 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $91.05 | Nov 2, 2017 | M | 1,796 | D | — | Feb 1, 2026 | Common Stock | 1,796 | 16,164 | D |
| Stock Option (Right to Buy)F8 | $109.14 | Nov 3, 2017 | M | 3,594 | D | — | Feb 2, 2025 | Common Stock | 3,594 | 17,969 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $143.54 (range $142.98 to $143.81).
- F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $144.89 (range $144.48 to $145.18).
- F5Open market sales reported on this line occurred at a weighted average price of $145.89 (range $145.63 to $146.04).
- F6Open market sales reported on this line occurred at a weighted average price of $144.69 (range $144.19 to $144.90).
- F7The option vests in 16 quarterly installments from 2/2/2016.
- F8The option vests in 16 quarterly installments from 2/3/2015.